B. J. Kennedy, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Hydroxyurea has antitumor activity in animals and man. It produces bone marrow suppression and megaloblastosis which are reversible after discontinuing treatment. Measurement of nucleic acid synthesis in mouse ascites tumor revealed a differential inhibition of deoxyribonucleic acid (DNA) synthesis in the presence of permissive ribonucleic acid synthesis. Almost 90% inhibition of DNA synthesis was seen at the higher concentrations of hydroxyurea. It is probable that hydroxyurea has more than one site of action to account for its effects.
The treatment of chronic myelogenous leukemia with hydroxyurea during the past 5 years in 20 patients demonstrates the beneficial effect of this
B. J. Kennedy. Hydroxyurea in Chronic Myelogenous Leukemia.. Ann Intern Med. 1969;70:1084–1085. doi: 10.7326/0003-4819-70-5-1084_3
Download citation file:
Published: Ann Intern Med. 1969;70(5):1084-1085.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use